A growing shortage of medications for a host of illnesses — from cancer to cystic fibrosis to cardiac arrest — has hospitals scrambling for substitutes to avoid patient harm, and sometimes even delaying treatment.
“It’s just a matter of time now before we call for a drug that we need to save a patient’s life and we find out there isn’t any,” says Dr. Eric J. Lavonas of the American College of Emergency Physicians.
The problem of scarce supplies or even unavailable medications isn’t a new one, but it’s getting markedly worse. The number listed in short supply has tripled over the past five years, to a record 211 medications last year. While some of those problems have been resolved, another 89 drug shortages occurred in the first three months of this year, according to the University of Utah’s Drug Information Service. It tracks shortages for the American Society of Health-System Pharmacists.
The vast majority involve injectable medications used mostly by medical centers — in emergency rooms, intensive care units and cancer wards. Particular shortages can last for weeks or for many months, and there aren’t always good alternatives. Nor is it just a U.S. problem, as other countries report some of the same supply disruptions.
It’s frightening for families.
At Miami Children’s Hospital, doctors had to postpone for a month the last round of chemotherapy for 14-year-old Caroline Pallidine because of a months-long nationwide shortage of cytarabine, a drug considered key to curing a type of leukemia.
“There’s always a fear, if she’s going so long without chemo, is there a chance this cancer’s going to come back?” says her mother, Marta Pallidine, who says she’ll be nervous until Caroline finishes her final treatments, scheduled for this week.
“In this day and age, we really shouldn’t be having this kind of problem and putting our children’s lives at risk,” she adds.
There are lots of causes, from recalls of contaminated vials, to trouble importing raw ingredients, to spikes in demand, to factories that temporarily shut down for quality upgrades.
Some experts pointedly note that pricier brand-name drugs seldom are in short supply. The Food and Drug Administration agrees that the overarching problem is that fewer and fewer manufacturers produce these older, cheaper generic drugs, especially the harder to make injectable ones. So if one company has trouble — or decides to quit making a particular drug -few others are able to ramp up their own production to fill the gap, says Valerie Jensen, who heads FDA’s shortage office.
The shortage that’s made the most headlines is a sedative used on death row, but on the health-care front, shortages are wide-ranging, including:
• Thiotepa, used with bone-marrow transplants.
• A whole list of electrolytes, injectable nutrients crucial for certain premature infants and tube-feeding of the critically ill.
• Norepinephrine injections for septic shock.
• A cystic fibrosis drug named acetylcysteine.